Tirzepatide Investigated for Body Weight Reduction in Participants with Obesity or Overweight in 72-Week Trial

Obesity and overweight are global health crises, significantly increasing risks for type 2 diabetes, cardiovascular disease, and certain cancers. Current weight management strategies, including lifestyle interventions and existing pharmacotherapies, often yield insufficient or unsustainable weight loss for many individuals. There's a critical need for more effective and well-tolerated pharmacological options that address the complex metabolic dysregulation underlying these conditions. Tirzepatide, a novel dual GLP-1R and GIP-R agonist, represents a promising therapeutic avenue by synergistically targeting multiple incretin pathways involved in glucose homeostasis, appetite regulation, and energy expenditure. This study aims to further elucidate its impact on body weight.

This randomized, double-blind, placebo-controlled clinical trial investigates Tirzepatide in participants with obesity or overweight. The main phase spans 72 weeks, with participants receiving Tirzepatide once weekly via subcutaneous injection. The primary objective is to assess its effect on body weight. Participants with prediabetes will continue into an extension phase for an additional 2 years. The study compares Tirzepatide against a placebo control arm.

The provided abstract describes the design and objectives of this clinical trial but does not present any specific results or numerical findings regarding the efficacy or safety of Tirzepatide. Therefore, detailed outcomes, statistical significance, or quantitative changes in body weight cannot be reported from this source. The study is designed to gather such data over its 72-week main phase and subsequent 2-year extension.